<DOC>
	<DOCNO>NCT00912691</DOCNO>
	<brief_summary>The purpose study determine whether CM-AT effective treating core symptom autism .</brief_summary>
	<brief_title>A Trial CM-AT Children With Autism- Open Label Extension Study</brief_title>
	<detailed_description>Autism currently significant cause disability pediatric population . CM-AT base upon observation many child autism digest protein . CM-AT proprietary enzyme design powder take three time day . It formulate release small intestine enhance protein digestion thus increase availability essential amino acid .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<criteria>Meets current Diagnostic Statistical Manual Mental Disorders ( DSMIVTR ) diagnostic criterion autistic disorder ( AD ) Ongoing 00102 Protocol require completion 00101 Protocol Now recruit subject directly 00102 Protocol Ongoing study require patient 38 year old weigh &lt; 11kg ( 24.2 lb . ) , achieve age 912 year old weigh &lt; 22kg ( 48.4 lbs. ) . Newly recruit subject must age 9 12 year old weigh &lt; 22kgs ( 48.4 lb . ) Demonstrated previous allergy porcine ( pork ) product Previous history severe head trauma stroke , seizure within one year enter study uncontrolled systemic disease Diagnosis : HIV , cerebral palsy , endocrine disorder , pancreatic disease Within 30 day start study , certain supplementation , chelation dietary restriction ( 30 day washout period would require inclusion ) Any use psychotropic medication , stimulant , SSRI 's must discontinue 30 day prior entrance</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Autism</keyword>
</DOC>